AUSTRALIAN men are invited to be the first to trial a new nasal spray for the treatment of Erectile Dysfunction (ED) called Spontan.
The clinical study followed the debut of its founding company LTR Pharma on the ASX last year.
LTR Pharma is a Brisbane-based biotechnology company with big ambitions to bring Spontan to market in Australia and the US.
It plans to do so within as little as 12-18 months, pending approval from key regulators such as the TGA and the US FDA.
This study is an essential clinical validation point for Spontan, allowing a small group of men to trial it first.
Spontan's nasal delivery technology bypasses the digestive system and is designed to overcome the issues of oral tablets for ED by having a "significantly faster onset of action within 10 minutes" - CLICK HERE to see how it works.
The spray's key peers include an established class of oral tablets called PDE5 inhibitors, encompassing household names like Viagra.
However, these tablets have a high discontinuation rate due to the lengthy wait time for the product to take effect, and the potential interference of normal digestion in their mechanism of action.
"Spontan is a truly innovative, fast-acting treatment for ED, which is on track to disrupt the established blockbuster oral PDE5 market," commented LTR Pharma Chair Lee Rodney.
"Current oral tablets can take up to one hour to take effect and many men are dissatisfied with the results as they don't always work or don't in the time desired.
"We welcome men in Australia to participate in this pivotal study, a crucial step in clinical validation and our expedited regulatory journey for Spontan, as we prepare to bring this product to the world."
See more information HERE. JG
The above article was sent to subscribers in Pharmacy Daily's issue from 20 Feb 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 20 Feb 24
